This guideline focuses on the diagnosis and staging of patients with ovarian cancer. It does not include recommendations covering every detail of diagnosis and staging. It focuses solely on areas of clinical practice that are known to be controversial or uncertain, where there is practice variation, where there is new or emerging evidence, or where there is potential for most impact. The aims and objectives of this guideline, along with the clinical question which addresses each one, are explicitly stated in Section 3.3 Aims and objectives. A systematic review of cost-effectiveness (Carty et al., 2018) was also carried out as part of the scope of work in collaboration with the Health Research Board - Collaboration in Ireland for Clinical Effectiveness Reviews (HRB-CICER). A budget impact analysis including the expected service and staff costs of implementing the recommendations is available in Section 3.15 Budget impact analysis. In areas where additional resources are required these will be sought through the service planning process.